A genetic instrument for Mendelian randomization of fibrinogen
- PMID: 22388766
- PMCID: PMC4181528
- DOI: 10.1007/s10654-012-9666-x
A genetic instrument for Mendelian randomization of fibrinogen
Abstract
Mendelian randomization studies on fibrinogen commonly use a single genetic variant as an instrument, but this may explain only a small proportion of the total phenotypic variance. We examined the contribution of multiple common single nucleotide polymorphisms (SNPs) and haplotypes in the entire fibrinogen gene cluster to plasma fibrinogen levels in two prospective cohorts, for use as instruments in future Mendelian randomization studies. Genotypes for 20 SNPs were determined in 2,778 middle-age (49-64 years) men from the Second-Northwick-Park-Heart Study (NPHS-II). These were replicated in 3,705 men from the Whitehall-II study (WH-II). Plasma fibrinogen levels were determined six times in NPHS-II and three times in WH-II. The minor alleles of four SNPs from the FGB gene, two from the FGA gene, and one from the FGG gene were associated with higher plasma fibrinogen levels. SNP rs1800790 (-455G>A) commonly used in Mendelian randomization studies was associated with R2=1.22% of the covariate adjusted residual variance in fibrinogen level. A variable selection procedure identified one additional SNP: rs2070011 (FGA) altogether explaining R2=1.45% of the residual variance in fibrinogen level. Using these SNPs no evidence for causality between the fibrinogen levels and coronary heart diseases was found in instrumental variables analysis. In the replication cohort, WH-II, the effects of the two SNPs on fibrinogen levels were consistent with the NPHS-II results. There is statistical evidence for several functional sites in the fibrinogen gene cluster that determine an individual's plasma fibrinogen levels. Thus, a combination of several SNPs will provide a stronger instrument for fibrinogen Mendelian randomization studies.
Figures


Similar articles
-
Fibrinogen beta variants confer protection against coronary artery disease in a Greek case-control study.BMC Med Genet. 2010 Feb 18;11:28. doi: 10.1186/1471-2350-11-28. BMC Med Genet. 2010. PMID: 20167083 Free PMC article.
-
APOE/C1/C4/C2 gene cluster genotypes, haplotypes and lipid levels in prospective coronary heart disease risk among UK healthy men.Mol Med. 2010 Sep-Oct;16(9-10):389-99. doi: 10.2119/molmed.2010.00044. Epub 2010 May 20. Mol Med. 2010. PMID: 20498921 Free PMC article.
-
Association study between variants in the fibrinogen gene cluster, fibrinogen levels and hypertension: results from the MONICA/KORA study.Thromb Haemost. 2009 Feb;101(2):317-24. Thromb Haemost. 2009. PMID: 19190816
-
Polygenic Mendelian Randomization.Cold Spring Harb Perspect Med. 2021 Feb 1;11(2):a039586. doi: 10.1101/cshperspect.a039586. Cold Spring Harb Perspect Med. 2021. PMID: 32229610 Free PMC article. Review.
-
Common pitfalls in drug target Mendelian randomization and how to avoid them.BMC Med. 2024 Oct 15;22(1):473. doi: 10.1186/s12916-024-03700-9. BMC Med. 2024. PMID: 39407214 Free PMC article. Review.
Cited by
-
Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study.J Am Coll Cardiol. 2016 Feb 2;67(4):407-416. doi: 10.1016/j.jacc.2015.10.086. J Am Coll Cardiol. 2016. PMID: 26821629 Free PMC article.
-
The Rotterdam Study: 2014 objectives and design update.Eur J Epidemiol. 2013 Nov;28(11):889-926. doi: 10.1007/s10654-013-9866-z. Epub 2013 Nov 21. Eur J Epidemiol. 2013. PMID: 24258680
-
The association between fibrinogen reactivity to mental stress and high-sensitivity cardiac troponin T in healthy adults.Psychoneuroendocrinology. 2015 Sep;59:37-48. doi: 10.1016/j.psyneuen.2015.05.002. Epub 2015 May 14. Psychoneuroendocrinology. 2015. PMID: 26010862 Free PMC article.
-
Using Mendelian Randomization studies to Assess Causality and Identify New Therapeutic Targets in Cardiovascular Medicine.Curr Genet Med Rep. 2016 Dec;4(4):207-212. doi: 10.1007/s40142-016-0103-4. Epub 2016 Sep 10. Curr Genet Med Rep. 2016. PMID: 29082115 Free PMC article.
-
Low-moderate urine arsenic and biomarkers of thrombosis and inflammation in the Strong Heart Study.PLoS One. 2017 Aug 3;12(8):e0182435. doi: 10.1371/journal.pone.0182435. eCollection 2017. PLoS One. 2017. PMID: 28771557 Free PMC article.
References
-
- Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294(14):1799–809. - PubMed
-
- Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet. 1987;1(8548):1452–5. - PubMed
-
- de Maat MP, Kastelein JJ, Jukema JW, et al. 455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arterioscler Thromb Vasc Biol. 1998;18(2):265–71. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- PG2005/014/BHF_/British Heart Foundation/United Kingdom
- RG/08/008/25291/BHF_/British Heart Foundation/United Kingdom
- 33014/PHS HHS/United States
- R01 HL036310/HL/NHLBI NIH HHS/United States
- G19/35/MRC_/Medical Research Council/United Kingdom
- G0100222/MRC_/Medical Research Council/United Kingdom
- AG13196/AG/NIA NIH HHS/United States
- DH_/Department of Health/United Kingdom
- R37 AG013196/AG/NIA NIH HHS/United States
- HL36310/HL/NHLBI NIH HHS/United States
- RG/08/008/BHF_/British Heart Foundation/United Kingdom
- HL036310/HL/NHLBI NIH HHS/United States
- R01 AG013196/AG/NIA NIH HHS/United States
- HS06516/HS/AHRQ HHS/United States
- PG/07/133/24260/BHF_/British Heart Foundation/United Kingdom
- RG/07/008/23674/BHF_/British Heart Foundation/United Kingdom
- G8802774/MRC_/Medical Research Council/United Kingdom
- G0902037/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Miscellaneous